-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Orbimed Advisors Llc Sells 153,897 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock
Orbimed Advisors Llc Sells 153,897 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) major shareholder Orbimed Advisors Llc sold 153,897 shares of the company's stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $31.96, for a total value of $4,918,548.12. Following the sale, the insider now owns 5,599,842 shares in the company, valued at approximately $178,970,950.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
SpringWorks Therapeutics Price Performance
SWTX stock opened at $30.42 on Friday. The company has a fifty day moving average price of $29.15 and a two-hundred day moving average price of $37.48. SpringWorks Therapeutics, Inc. has a one year low of $13.60 and a one year high of $77.70. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -6.53 and a beta of 0.85.
Get SpringWorks Therapeutics alerts:SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.15). During the same period in the previous year, the company earned ($0.97) EPS. The firm's revenue for the quarter was up .0% on a year-over-year basis. Research analysts anticipate that SpringWorks Therapeutics, Inc. will post -5.36 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on SWTX. The Goldman Sachs Group dropped their price objective on SpringWorks Therapeutics from $92.00 to $76.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th. HC Wainwright upped their price objective on SpringWorks Therapeutics from $94.00 to $103.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Wedbush set a $53.00 price target on SpringWorks Therapeutics in a research note on Monday, June 20th.Institutional Investors Weigh In On SpringWorks Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Parallel Advisors LLC lifted its holdings in shares of SpringWorks Therapeutics by 34.7% during the first quarter. Parallel Advisors LLC now owns 1,028 shares of the company's stock worth $61,000 after buying an additional 265 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in SpringWorks Therapeutics by 8.1% in the 1st quarter. Teacher Retirement System of Texas now owns 4,099 shares of the company's stock valued at $231,000 after purchasing an additional 307 shares during the period. Royal Bank of Canada boosted its holdings in SpringWorks Therapeutics by 1.8% in the 1st quarter. Royal Bank of Canada now owns 26,465 shares of the company's stock valued at $1,494,000 after purchasing an additional 479 shares during the period. US Bancorp DE boosted its holdings in SpringWorks Therapeutics by 20.7% in the 2nd quarter. US Bancorp DE now owns 3,246 shares of the company's stock valued at $80,000 after purchasing an additional 556 shares during the period. Finally, Credit Suisse AG boosted its holdings in SpringWorks Therapeutics by 3.0% in the 2nd quarter. Credit Suisse AG now owns 19,510 shares of the company's stock valued at $480,000 after purchasing an additional 566 shares during the period.
About SpringWorks Therapeutics
(Get Rating)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
See Also
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) major shareholder Orbimed Advisors Llc sold 153,897 shares of the company's stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $31.96, for a total value of $4,918,548.12. Following the sale, the insider now owns 5,599,842 shares in the company, valued at approximately $178,970,950.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
SpringWorks治疗公司(纳斯达克代码:SWTX-GET评级)的大股东Orbimed Advisors LLC在9月12日(星期一)的一笔交易中出售了153,897股公司股票。这只股票的平均售价为31.96美元,总价值为4918,548.12美元。出售后,这位内部人士现在拥有该公司5,599,842股,价值约178,970,950.32美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,用户可以通过以下链接访问该文件。持有公司10%或以上股份的大股东必须披露他们与美国证券交易委员会的交易。
SpringWorks Therapeutics Price Performance
SpringWorks治疗公司的性价比
SWTX stock opened at $30.42 on Friday. The company has a fifty day moving average price of $29.15 and a two-hundred day moving average price of $37.48. SpringWorks Therapeutics, Inc. has a one year low of $13.60 and a one year high of $77.70. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -6.53 and a beta of 0.85.
上周五,SWTX股价开盘报30.42美元。该公司的50日移动平均价为29.15美元,200日移动平均价为37.48美元。SpringWorks治疗公司的一年低点为13.60美元,一年高位为77.70美元。该股市值为15亿美元,市盈率为-6.53倍,贝塔系数为0.85。
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.15). During the same period in the previous year, the company earned ($0.97) EPS. The firm's revenue for the quarter was up .0% on a year-over-year basis. Research analysts anticipate that SpringWorks Therapeutics, Inc. will post -5.36 EPS for the current fiscal year.
SpringWorks治疗公司(纳斯达克代码:SWTX-GET Rating)最近一次发布季度收益数据是在8月4日星期四。该公司公布了该季度每股收益(1.41美元),低于分析师普遍预期的(1.26美元)和(0.15美元)。去年同期,该公司每股收益为0.97美元。该公司当季营收较上年同期增长0.0%。研究分析师预计,SpringWorks治疗公司本财年将公布每股收益5.36美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Institutional Investors Weigh In On SpringWorks Therapeutics
机构投资者看好SpringWorks治疗公司
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Parallel Advisors LLC lifted its holdings in shares of SpringWorks Therapeutics by 34.7% during the first quarter. Parallel Advisors LLC now owns 1,028 shares of the company's stock worth $61,000 after buying an additional 265 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in SpringWorks Therapeutics by 8.1% in the 1st quarter. Teacher Retirement System of Texas now owns 4,099 shares of the company's stock valued at $231,000 after purchasing an additional 307 shares during the period. Royal Bank of Canada boosted its holdings in SpringWorks Therapeutics by 1.8% in the 1st quarter. Royal Bank of Canada now owns 26,465 shares of the company's stock valued at $1,494,000 after purchasing an additional 479 shares during the period. US Bancorp DE boosted its holdings in SpringWorks Therapeutics by 20.7% in the 2nd quarter. US Bancorp DE now owns 3,246 shares of the company's stock valued at $80,000 after purchasing an additional 556 shares during the period. Finally, Credit Suisse AG boosted its holdings in SpringWorks Therapeutics by 3.0% in the 2nd quarter. Credit Suisse AG now owns 19,510 shares of the company's stock valued at $480,000 after purchasing an additional 566 shares during the period.
一些对冲基金和其他机构投资者最近调整了对该公司的持股。平行顾问有限责任公司在第一季度增持了34.7%的SpringWorks Treateutics股票。Parly Advisors LLC现在拥有1,028股该公司股票,价值61,000美元,上个季度又购买了265股。德克萨斯州教师退休系统第一季度增持SpringWorks治疗公司8.1%的股份。德克萨斯州教师退休系统在此期间额外购买了307股,现在拥有该公司4,099股股票,价值231,000美元。加拿大皇家银行在第一季度增持了SpringWorks治疗公司1.8%的股份。加拿大皇家银行在此期间又购买了479股,现在持有26,465股该公司股票,价值1,494,000美元。US Bancorp DE在第二季度增持了SpringWorks Treeutics 20.7%的股份。US Bancorp DE现在拥有3246股该公司的股票,价值8万美元,在此期间又购买了556股。最后,瑞士信贷(Credit Suisse AG)在第二季度增持了SpringWorks Treeutics 3.0%的股份。瑞士信贷(Credit Suisse AG)在此期间又购买了566股,目前持有该公司19,510股股票,价值48万美元。
About SpringWorks Therapeutics
关于SpringWorks治疗公司
(Get Rating)
(获取评级)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
SpringWorks治疗公司为患有罕见疾病和癌症的未得到充分服务的患者群体收购、开发和商业化药物。它的主要候选产品是Niroacestat,一种口服小分子伽马分泌酶抑制剂,正在进行治疗韧带样肿瘤的第三阶段临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 免费获取StockNews.com关于SpringWorks治疗公司(SWTX)的研究报告
- 没有人告诉这三只股票这是下跌的一周
- 有什么办法可以治愈Teladoc股票的问题吗?
- 为什么医疗产品制造商Repligen可能成为潜在收购对象
- 在10%的水平上,Arbor Realty Trust的股息值得吗?
- 投资者应关注RF Industries
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得SpringWorks治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对SpringWorks Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧